JPMorgan lowered the firm’s price target on U.S. Physical Therapy to $99 from $108 and keeps an Overweight rating on the shares. The analyst reassessed the firm’s healthcare services coverage universe post the Q3 reports. The firm thinks the 2024 setup for managed care is “more varied and complicated” post Q3. Medicaid looks “more ownable” but Q4 will be a key confirmatory data point, Medicare Advantage utilization concerns are back in focus, and there is speculation of one last managed care mega merger, the analyst tells investors in a research note. All in, JPMorgan continues to prefer diversified managed care operators at this stage from a “purely fundamental perspective.” On distributors, the firm says volumes remained strong as GLP-1 volumes and lower generic conversions and continued growth in specialty benefitted revenue growth, and continue to lead to a positive set up heading into the end of 2023.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on USPH:
- U.S. Physical Therapy price target lowered to $111 from $124 at Barrington
- U.S. Physical Therapy reports Q3 adjusted EPS 62c, consensus 61c
- USPH Earnings this Week: How Will it Perform?
- U.S. Physical Therapy acquires an injury prevention, ergonomics business for $4M
- U.S. Physical Therapy acquires two physical therapy practices for $13.9M